Every material Form 8-K BridgeBio Pharma, Inc. has filed with the SEC since August 31, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
BridgeBio reported third quarter 2026 total revenues of $353.2 million, up from $120.7 million a year earlier, driven by $253.2 million of U.S. Attruby net product revenue and a one-time $75.0 million Bayer sales milestone. Loss from operations narrowed to $11.6 million from $145.2 million, but net loss attributable to common stockholders was $83.0 million, or $0.42 per share, after $26.3 million in preferred stock dividends and accretion.
Total revenues, net of $353.2 million, up from $120.7 million in Q3 2025
U.S. Attruby net product revenue of $253.2 million; license and services revenue of $79.3 million included the $75.0 million Bayer milestone
Loss from operations of $11.6 million versus $145.2 million a year earlier
Cash, cash equivalents and marketable securities of $1.5 billion as of September 30, 2026; BBP-418 PDUFA date is November 27, 2026
BridgeBio announced the FDA accepted its New Drug Application for oral infigratinib for children with achondroplasia with Priority Review, setting a PDUFA target action date of February 4, 2027. The company says the drug met its Phase 3 PROPEL 3 primary endpoint, but the filing does not describe financial results or a financial effect, so the update is mainly a regulatory milestone for shareholders.
FDA accepted the NDA with Priority Review; PDUFA target action date is February 4, 2027
PROPEL 3 met its primary endpoint: LS mean treatment difference of +1.74 cm/year and mean treatment difference of +2.10 cm/year in annualized height velocity (p<0.0001)
Oral infigratinib has Breakthrough Therapy Designation; BridgeBio plans to submit a Marketing Authorization Application to the EMA in Q4 2026
Approval is not assured; the filing notes the FDA may not approve the drug on the anticipated timeline or at all
BridgeBio entered a voluntary agreement with the U.S. government to expand Medicaid access to Attruby through the GENEROUS Model and lower drug costs. The company says it does not expect to be subject to future pricing mandates, and the specific terms remain confidential.
Agreement expands state Medicaid access to Attruby via the GENEROUS Model; specific terms are confidential
BridgeBio does not expect future pricing mandates; pricing commitments for future medicines are expected to exclude medicines approved exclusively for orphan indications
ForgingBridges copay program is unaffected and can reduce out-of-pocket costs to as little as $0 per month
Pending FDA reviews include BBP-418 (PDUFA November 27, 2026) and encaleret (PDUFA May 7, 2027)
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every BridgeBio Pharma, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →